Here are the 10-Q quarterly reports from FMC Corporation (FMC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FMC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FMC filings page.
FMC Corporation reported third-quarter revenue of $105.9 million, versus $542.2 million a year earlier, and a net loss attributable to FMC stockholders of $2,066.9 million, compared with $569.3 million. For the first nine months of 2026, revenue was $1,731.6 million versus $2,384.1 million, and stockholder net loss was $2,534.8 million versus $518.1 million. Revenue included approximately $639 million of charges tied to commercial actions; continuing-operations cash used was $231.3 million versus $663.3 million.
In September 2026, Tessenderlo Group bought 30,319,166 FMC shares at $13.30 each, representing approximately 20% of outstanding shares; FMC received $403.2 million and used proceeds to pay down Revolving Credit Facility borrowings and for general corporate purposes. Under a June agreement with Corteva, FMC retains ownership of rimisoxafen and received a $200.0 million initial prepurchase payment for supply.
FMC signed an agreement to sell its India commercial business to Crystal Crop Protection Limited for $252 million, subject to customary adjustments for cash, debt and working capital; closing was expected during 2026. FMC also recorded a $287.5 million non-cash impairment of crop-protection brand intangibles during the nine months.
For the quarter ended June 30, 2026, FMC Corporation reported revenue of $867.1 million, down from $1,050.5 million a year earlier, and a net loss attributable to stockholders of $186.6 million versus prior net income of $66.7 million. Diluted EPS was $(1.49), including $222.3 million of restructuring and other charges tied to Project Foundation, manufacturing exits, the India business held for sale and environmental items.
For the first half of 2026, FMC generated revenue of $1,625.7 million and a net loss of $467.9 million, with $299.3 million of restructuring and other charges and an additional $123 million valuation allowance on Swiss deferred tax assets. Operating cash flow from continuing operations was $(237.9 million). The company issued $1.2 billion of 8.0% Senior Secured Notes due 2031, received a $200.0 million prepurchase payment under a rimisoxafen license with Corteva, and ended June 30, 2026 with $476.6 million of cash and $4,280.6 million of total debt.
FMC Corporation reported a sharp downturn for Q3 2025. Net loss attributable to stockholders was $569.3 million on revenue of $542.2 million, compared with $65.0 million profit on $1,065.4 million revenue a year ago. Results were driven by actions to prepare the India commercial business for sale.
The India plan triggered approximately $510 million in total adjustments, including $419 million of revenue charges and a $226.8 million asset impairment, partially offset by a $144 million credit to cost of sales. Assets held for sale were $826.5 million; net assets were $450.0 million.
Year-to-date operating cash flow was $(663.3) million. Debt activity included issuing $750 million 8.45% Subordinated Notes and redeeming $500 million of 2026 senior notes; commercial paper rose to $981.8 million. Leverage was 4.94 versus a 5.25 maximum, and interest coverage was 3.93 versus a 3.00 minimum; the company was in covenant compliance. Common shares outstanding were 124,920,067 as of September 30, 2025.